Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02619669
Recruitment Status : Recruiting
First Posted : December 2, 2015
Last Update Posted : May 6, 2019
Sponsor:
Information provided by (Responsible Party):
Gary Schwartz, Dartmouth-Hitchcock Medical Center

Brief Summary:

Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.

The mTOR complex (mTORC) is an important therapeutic target that is generally stable (i.e., low tendency to mutate) and is a key intracellular point of convergence for a number of cellular signaling pathways. Inhibiting mTOR may inhibit abnormal cell proliferation, tumor angiogenesis, and abnormal cellular metabolism, thus providing the rationale for mTOR inhibitors as potential agents in the treatment of a number of indications including solid tumor and hematological malignancies, as either monotherapy or in combination with other chemotherapeutic agents. Like rapamycin, several newly approved rapalogs (temsirolimus and everolimus) are specific and allosteric inhibitors of mTORC1, and only partially inhibit mTORC1 signaling pathways. They do not directly inhibit mTORC2, which has shown to be an emerging target in cancer research. TAK-228 was developed to address the incomplete inhibition of the mTOR pathway by rapalogs.

Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.

The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: TAK-228 Drug: Letrozole Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Actual Study Start Date : April 20, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Letrozole

Arm Intervention/treatment
Experimental: TAK-228 followed by TAK-228 plus Letrozole

Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.

The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects.

Drug: TAK-228
Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.

Drug: Letrozole
An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
Other Name: Femara




Primary Outcome Measures :
  1. Evaluation of Treatment-Related Adverse Events as Assessed by NCI CTCAE v4.0 [ Time Frame: 1 year ]
    Determine the safety of the combination of TAK-228 and Letrozole in women with early-stage ER+/HER2- breast cancer at high risk for recurrence.


Secondary Outcome Measures :
  1. Pathologic Response Assessed by Analysis of Tissue Samples and RECIST Criteria [ Time Frame: 1 year ]
    Determine the rates of clinical and pathologic response to treatment with the combination of TAK-228 and Letrozole in women with early-stage ER+/HER2- breast cancer at high risk for recurrence.


Other Outcome Measures:
  1. Tumor Effects Assessed by Analysis of Tissue Samples [ Time Frame: 1 year ]
    Determine the effects of treatment with TAK-228 and Letrozole/TAK-228 on the tumor phosphoproteome to comprehensively profile drug effects on kinase signaling, and to identify compensatory oncogenic signaling pathways.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Each patient must meet all of the following inclusion criteria to be enrolled in the study:

  1. Post-menopausal women ≥18 years of age with clinical stage I-IV, ER positive / HER2 negative, breast cancer that will be managed by surgical resection.

    The subject is post-menopausal if:

    • She has had a prior bilateral oophorectomy
    • Age is 60 or greater
    • Age is under 60 but she has had at least 12 months or amenorrhea and with both follicle-stimulating hormone and estradiol levels in the post-menopausal range. Treatment with a luteinizing hormone-releasing hormone is not allowed for induction of ovarian suppression on this trial.

    Patients with metastatic disease at diagnosis are eligible if clinically appropriate.

    The patient must have had a baseline MRI performed as standard-of-care that can be used to calculate the distance(s) of the longest dimension(s) of the primary tumor(s).

  2. Histologic documentation of breast cancer by core needle or incisional biopsy.
  3. Tumor size must be ≥ 2 cm in the longest dimension.
  4. Patients must be at high risk for recurrence, which will be defined during the pre-treatment screening period as meeting one of the following criteria:

    1. A histologically positive nodal deposit ≥0.2 mm
    2. Histologic Grade 3
    3. Peritumoral lymphatic vessel or vascular invasion
    4. Oncotype Dx score of 25 or greater
  5. The invasive cancer must be HER2-low, defined as IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been performed.
  6. The invasive cancer must be estrogen receptor alpha (ER)-positive, defined as having ER staining by IHC in ≥10% of malignant tumor cells.
  7. The subject must be deemd appropriate for neoadjuvant endocrine therapy by the referring medical oncologist.
  8. The subject must agree to 4 months (120 days) of neoadjuvant treatment with TAK-228 and Letrozole, have blood draws and urine samples obtained, have research tumor biopsies performed at baseline and after 10 days of TAK-228 treatment, and have a repeat MRI performed prior to surgery (MRI is part of routine clinical care).
  9. ECOG performance status 0-1.
  10. Life expectancy of 12 months or longer.
  11. Adequate hematologic, hepatic, renal, and glycemic function:

    1. Adequate bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L; hemoglobin ≥ 9 g/dL;
    2. Hepatic: total bilirubin ≤ 1.5 x upper limit of normal (ULN), transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase-AST/SGOT and alanine aminotransferase/serum glutamic pyruvic transaminase-ALT/SGPT) ≤ 2.5 x ULN;
    3. Renal: creatinine clearance ≥50 mL/min based either on Cockcroft-Gault estimate from serum creatinine or based on urine collection (12 or 24 hour);
    4. Metabolic: fasting serum glucose (≤ 130 mg/dL) and fasting triglycerides ≤ 300 mg/dL;
  12. Ability to swallow oral medications and maintain an empty stomach state for two hours prior to the TAK-228 dose and for one hour following administration.
  13. Ability to give informed consent.

Exclusion Criteria

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  1. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  2. Any other presurgical therapy for breast cancer.
  3. Prior anti-estrogen therapy within the last 5 years.
  4. Prior treatment with an mTOR, AKT, or PI3K inhibitor.
  5. Treatment within the past two years with a bisphosphonate or a Rank ligand inhibitor.
  6. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, subjects with enteric stomata are also excluded.
  7. Poorly controlled diabetes mellitus defined as HbA1c > 7%. Subjects with a history of transient glucose intolerance due to corticosteroid administration are allowed in this study if all other inclusion/exclusion criteria are met.
  8. History of any of the following within the last 6 months prior to study entry:

    1. Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures.
    2. Ischemic cerebrovascular event, including TIA and artery revascularization procedures.
    3. Requirement for inotropic support (excluding digoxin) or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation or ventricular tachycardia).
    4. Placement of a pacemaker for control of rhythm.
    5. New York Heart Association (NYHA) Class III or IV heart failure (See Appendix B).
    6. Pulmonary embolism.
  9. Significant active cardiovascular or pulmonary disease at the time of study entry, including:

    1. Uncontrolled high blood pressure (i.e., systolic blood pressure >180 mm Hg, diastolic blood pressure > 95 mm Hg)
    2. Pulmonary hypertension
    3. Uncontrolled asthma or O2 saturation < 90% by ABG (Arterial Blood Gas) analysis or pulse oximetry on room air
    4. Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement
    5. Medically significant (symptomatic) bradycardia
    6. History of arrhythmia requiring an implantable cardiac defibrillator
    7. Baseline prolongation of the rate-corrected QT interval (QTc) (e.g., repeated demonstration of QTc interval > 480 milliseconds, or history of congenital long QT syndrome, or torsade de pointes) Confidential v03January2017 40
  10. Treatment with strong CYP3A4 and CYP2C19 inhibitors and/or inducers must be discontinued at least 1 week before administration of the first dose of study drug.(see Appendix C)
  11. Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either IV or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for ≥ 4 weeks are eligible).
  12. Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active infection, or any other condition that could compromise participation of the patient in the study.
  13. Central nervous system (CNS) metastasis.
  14. Known human immunodeficiency virus infection.
  15. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
  16. Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug.
  17. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within 7 days before receiving the first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02619669


Contacts
Layout table for location contacts
Contact: Gary Schwartz, MD (800) 639-6918 Cancer.Research.Nurse@Dartmouth.edu

Locations
Layout table for location information
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Gary Schwartz, MD    800-639-6918    Cancer.Research.Nurse@Dartmouth.edu   
Sub-Investigator: Todd Miller, Ph.D         
Sub-Investigator: Mary Chamberlin, MD         
Sub-Investigator: Peter Kaufman, MD         
Sub-Investigator: Brad Arrick, MD         
Sponsors and Collaborators
Gary Schwartz
Investigators
Layout table for investigator information
Principal Investigator: Gary Schwartz, MD Dartmouth-Hitchcock Medical Center

Layout table for additonal information
Responsible Party: Gary Schwartz, Staff Physician, Hematology-Oncology, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT02619669     History of Changes
Other Study ID Numbers: D14012
First Posted: December 2, 2015    Key Record Dates
Last Update Posted: May 6, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gary Schwartz, Dartmouth-Hitchcock Medical Center:
Neoadjuvant
TAK-228 (MLN0128)
Letrozole
ER+
HER2-
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Letrozole
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs